Yükleniyor... / Loading...
This study examines whether adding the hormone Triiodothyronine (T3) to electroconvulsive therapy (ECT) helps speed recovery and prevent relapse in patients with major depression. It included hospitalized patients aged 18-64 with unipolar major depression who were recommended for ECT. It was carried out as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Ages 18-64, male and female, any race/ethnicity * Current diagnosis of major depression (unipolar) * Currently Hospitalized at Mayo Clinic Physician recommendation for ECT treatment at Mayo Clinic * Willing to return to Mayo Clinic for follow-up Exclusion Criteria: * Inability to speak English * Inability or unwillingness to provide written informed consent * Psychotic depression (SCID-confirmed) * Court-ordered involuntary ECT * Currently receiving maintenance ECT * Unstable current medical condition * A condition that would deem triiodothyronine treatment unsafe * Diagnosis of primary thyroid disorder * Lithium treatment within 6 weeks of randomization * Currently taking levothyroxine (Synthroid®) or triiodothyronine (Cytomel®) * Subclinical hypo- or hyperthyroidism * History of atrial fibrillation or any cardiac arrhythmia except sinus bradycardia * History of myocardial infarction within the past 12 months or unstable coronary artery disease * Pregnancy * History of Osteoporosis